Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

April 29, 2020 21:49 ET | Source: Recce Pharmaceuticals

Recce Pharmaceuticals Announces First-Quarter 2020 Financial Results and Provides Operational Highlights

Highlights: Strong cash position with reserves of AUD $4.09MFormalized a Phase I Clinical trial agreement to conduct a first-in-human study of RECCE® 327Completed successful in-vivo toxicity...
April 23, 2020 08:35 ET | Source: Recce Pharmaceuticals

Recce Pharmaceuticals Announces More Positive Data on RECCE® 327 Against MRSA Superbug in Burn Wound Animal Model

Highlights: Statistically significant reduction in MRSA superbug bacterial load and higher percentage of wound contraction with RECCE® 327 as compared to Soframycin in rat model for topical...
April 20, 2020 08:00 ET | Source: Recce Pharmaceuticals

Recce Pharmaceuticals Announces Positive Data on RECCE® 327 Against Influenza A Respiratory Virus Infection in Animal Model

Highlights: Dramatic reduction in viral load in the lungs of mice treated with RECCE® 327 as compared to the approved antiviral drug treated and vehicle control untreated groupsRECCE® 327’s unique...
April 08, 2020 08:34 ET | Source: Recce Pharmaceuticals

Recce Signs Phase I Clinical Trial Agreement to Initiate Study of Synthetic Antibiotic RECCE® 327 in Healthy Subjects

Highlights: Phase I trial agreement with leading clinical research organization Human safety and tolerability study to assess infusion of RECCE® 327 in 40 healthy subjects as a single ascending...